Vigabatrin.
Mumford
J P
JP
Merrell Dow Research Institute, Winnersh, Berkshire, UK.
Lewis
P J
PJ
D000614:Aminocaproates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005071:Evoked Potentials / Q000187:drug effects; D006801:Humans; D051379:Mice; D051381:Rats; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D015507:Drugs, Investigational; D020888:Vigabatrin